Adrenergic beta-Antagonists

• 

  Subject Areas on Research

  • 2007 Focused Update of the ACC/AHA 2004 Guidelines for the Management of Patients With ST-Elevation Myocardial Infarction: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines: developed in collaboration With the Canadian Cardiovascular Society endorsed by the American Academy of Family Physicians: 2007 Writing Group to Review New Evidence and Update the ACC/AHA 2004 Guidelines for the Management of Patients With ST-Elevation Myocardial Infarction, Writing on Behalf of the 2004 Writing Committee. 
  • 2012 ACCF/AHA/ACP/AATS/PCNA/SCAI/STS Guideline for the diagnosis and management of patients with stable ischemic heart disease: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines, and the American College of Physicians, American Association for Thoracic Surgery, Preventive Cardiovascular Nurses Association, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons. 
  • 2018 ACC/AHA/HRS Guideline on the Evaluation and Management of Patients With Bradycardia and Cardiac Conduction Delay: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society. 
  • A Composite Score Summarizing Use and Dosing of Evidence-Based Medical Therapies in Heart Failure: A Nationwide Cohort Study. 
  • A beta-blocker, propranolol, decreases the efficacy from enzyme replacement therapy in Pompe disease. 
  • A case of electrical storm in a liver transplant patient. 
  • A fraction of the ventricular myocardium that has the specificity of the cardiac beta-adrenergic receptor. 
  • A meta-analysis of CYP2D6 metabolizer phenotype and metoprolol pharmacokinetics. 
  • A randomized trial of direct-to-patient communication to enhance adherence to beta-blocker therapy following myocardial infarction. 
  • A unique mechanism of beta-blocker action: carvedilol stimulates beta-arrestin signaling. 
  • ACCF/AHA/AMA-PCPI 2011 performance measures for adults with coronary artery disease and hypertension: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Performance Measures and the American Medical Association-Physician Consortium for Performance Improvement. 
  • ACCF/AHA/AMA-PCPI 2011 performance measures for adults with coronary artery disease and hypertension: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Performance Measures and the American Medical Association-Physician Consortium for Performance Improvement. 
  • ACP Journal Club. Review: in patients with heart failure, β-blockers reduce mortality but do not differ from each other. 
  • ACP Journal Club: pooled RCTs: β-blockers reduce mortality in heart failure patients with sinus rhythm but not in those with AF. 
  • Achieving a Maximally Tolerated β-Blocker Dose in Heart Failure Patients: Is There Room for Improvement? 
  • Acquired dynamic left ventricular outflow tract obstruction complicating acute anterior myocardial infarction: serial echocardiographic and clinical evaluation. 
  • Acute coronary syndromes and diabetes mellitus. 
  • Acute depression of myocardial beta-adrenergic receptor signaling during cardiopulmonary bypass: impairment of the adenylyl cyclase moiety. Duke Heart Center Perioperative Desensitization Group. 
  • Adherence to evidence-based therapies after discharge for acute coronary syndromes: an ongoing prospective, observational study. 
  • Adrenergic receptor function in panic disorder. II. Neutrophil beta 2 receptors: Gs protein coupling, effects of imipramine treatment and relationship to treatment outcome. 
  • Adrenergic receptors: biochemistry, regulation, molecular mechanism, and clinical implications. 
  • Adrenomedullary function in the neonatal rat: responses to acute hypoxia. 
  • Affinity chromatography of the beta-adrenergic receptor and characterization of antibodies raised against purified receptor preparations. 
  • After myocardial infarction. How to determine future risk and what to do then. 
  • Agonist-induced increase in apparent beta-adrenergic receptor size. 
  • Alcohol septal ablation for the treatment of hypertrophic obstructive cardiomyopathy. A multicenter North American registry. 
  • Allosteric "beta-blocker" isolated from a DNA-encoded small molecule library. 
  • Alpha-1 adrenoceptor-angiotensin II type 1 receptor cross-talk and its relevance in clinical medicine. 
  • Alpha-2 receptors mediate an endogenous noradrenergic suppression of kindling development. 
  • Altered airway and cardiac responses in mice lacking G protein-coupled receptor kinase 3. 
  • An analysis of the Association of Society of Chest Pain Centers Accreditation to American College of Cardiology/American Heart Association non-ST-segment elevation myocardial infarction guideline adherence. 
  • Anti-beta(1)-adrenergic receptor antibodies and heart failure: causation, not just correlation. 
  • Antianginal medications and long-term outcomes after elective catheterization in patients with coronary artery disease. 
  • Antibodies raised against purified beta-adrenergic receptors specifically bind beta-adrenergic ligands. 
  • Antihypertensive drug exposure in premature infants from 1997 to 2013. 
  • Antihypertensive medications and risk of death and hospitalizations in US hemodialysis patients: Evidence from a cohort study to inform hypertension treatment practices. 
  • Assessing oral beta-blocker therapy after percutaneous coronary intervention for ST-segment elevation myocardial infarction: the role of observational data. 
  • Association between adrenergic receptor genotypes and beta-blocker dose in heart failure patients: analysis from the HF-ACTION DNA substudy. 
  • Association between mortality and persistent use of beta blockers and angiotensin-converting enzyme inhibitors in patients with left ventricular systolic dysfunction and coronary artery disease. 
  • Association between patient beliefs and medication adherence following hospitalization for acute coronary syndrome. 
  • Association between performance measures and clinical outcomes for patients hospitalized with heart failure. 
  • Association between resting heart rate, chronotropic index, and long-term outcomes in patients with heart failure receiving β-blocker therapy: data from the HF-ACTION trial. 
  • Association of Changes in Heart Failure Treatment With Patients' Health Status: Real-World Evidence From CHAMP-HF. 
  • Association of Systemic Medication Use With Intraocular Pressure in a Multiethnic Asian Population: The Singapore Epidemiology of Eye Diseases Study. 
  • Association of US Centers for Medicare and Medicaid Services Hospital 30-Day Risk-Standardized Readmission Metric With Care Quality and Outcomes After Acute Myocardial Infarction: Findings From the National Cardiovascular Data Registry/Acute Coronary Treatment and Intervention Outcomes Network Registry-Get With the Guidelines. 
  • Association of a P2Y12 Inhibitor Copayment Reduction Intervention With Persistence and Adherence With Other Secondary Prevention Medications: A Post Hoc Analysis of the ARTEMIS Cluster-Randomized Clinical Trial. 
  • Association of beta-blocker use and selectivity with outcomes in patients with heart failure and chronic obstructive pulmonary disease (from OPTIMIZE-HF). 
  • Association of hospital myocardial infarction volume with adherence to American College of Cardiology/American Heart Association performance measures: Insights from the National Cardiovascular Data Registry. 
  • Associations between β-blocker therapy and cardiovascular outcomes in patients with diabetes and established cardiovascular disease. 
  • Atenolol use and clinical outcomes after thrombolysis for acute myocardial infarction: the GUSTO-I experience. Global Utilization of Streptokinase and TPA (alteplase) for Occluded Coronary Arteries. 
  • Atrial fibrillation and acute myocardial infarction: antithrombotic therapy and outcomes. 
  • Atrial fibrillation and obstructive lung disease: Don't fear the β-blocker. 
  • Beta 1-selective and non-selective beta-adrenoceptor blockade, anaerobic threshold and respiratory gas exchange during exercise. 
  • Beta-2 adrenergic control of ornithine decarboxylase activity in brain regions of the developing rat. 
  • Beta-Blockers for Primary Therapy of Heart Failure With Preserved Ejection Fraction: An Idea Whose Time Has Gone? 
  • Beta-adrenergic receptor desensitization in cardiac hypertrophy and heart failure. 
  • Beta-adrenergic receptors: biochemical mechanisms of physiological regulation. 
  • Beta-adrenergic receptors: recognition and regulation. 
  • Beta-adrenergic regulation of cholecystokinin secretion in STC-1 cells. 
  • Beta-blocker and ACE-inhibitor dosing as a function of body surface area: From the HF-ACTION trial. 
  • Beta-blocker prophylaxis for total knee arthroplasty patients: a case series. 
  • Beta-blocker therapy for heart failure: the evidence is in, now the work begins. 
  • Beta-blocker therapy in advanced heart failure: clinical characteristics and long-term outcomes. 
  • Beta-blocker therapy in non-cardiac surgery. 
  • Beta-blocker use and outcomes among hospitalized heart failure patients. 
  • Beta-blockers alprenolol and carvedilol stimulate beta-arrestin-mediated EGFR transactivation. 
  • Beta-blockers and depression. 
  • Beta1-adrenergic receptors maintain fetal heart rate and survival. 
  • Between Scylla and Charybdis: The choice of inotropic agent for decompensated heart failure. 
  • Biopsychosocial influence on shoulder pain: Rationale and protocol for a pre-clinical trial. 
  • Blunted cyclic variation of heart rate predicts mortality risk in post-myocardial infarction, end-stage renal disease, and chronic heart failure patients. 
  • Bucindolol Decreases Atrial Fibrillation Burden in Patients With Heart Failure and the ADRB1 Arg389Arg Genotype. 
  • Bucindolol for the Maintenance of Sinus Rhythm in a Genotype-Defined HF Population: The GENETIC-AF Trial. 
  • Bucindolol hydrochloride in atrial fibrillation and concomitant heart failure. 
  • Bucindolol: new hopes from reviewing past data. 
  • CASE 6--2012: suspected amiodarone hepatotoxicity after cardiac surgery. 
  • CLINICAL PRACTICE. Chronic Stable Angina. 
  • Cardiac adrenergic receptors. 
  • Cardiac beta ARK1 inhibition prolongs survival and augments beta blocker therapy in a mouse model of severe heart failure. 
  • Cardiac function and heart failure. 
  • Cardiovascular medications and survival in people with ovarian cancer: A population-based cohort study from British Columbia, Canada. 
  • Cardiovascular outcomes in the African American Study of Kidney Disease and Hypertension (AASK) Trial. 
  • Carvedilol use at discharge in patients hospitalized for heart failure is associated with improved survival: an analysis from Organized Program to Initiate Lifesaving Treatment in Hospitalized Patients with Heart Failure (OPTIMIZE-HF). 
  • Catecholamine binding to the beta-adrenergic receptor. 
  • Catecholamine-induced desensitization of turkey erythrocyte adenylate cyclase. Structural alterations in the beta-adrenergic receptor revealed by photoaffinity labeling. 
  • Catecholamines act via a beta-adrenergic receptor to maintain fetal heart rate and survival. 
  • Central corneal thickness and measured IOP response to topical ocular hypotensive medication in the Ocular Hypertension Treatment Study. 
  • Changes in Medical Therapy and Lifestyle After Anatomical or Functional Testing for Coronary Artery Disease. 
  • Characteristics of treated hypertension in incident hemodialysis and peritoneal dialysis patients. 
  • Characteristics, management, and outcomes of cocaine-positive patients with acute coronary syndrome (from the National Cardiovascular Data Registry). 
  • Characteristics, treatments, and outcomes of patients with preserved systolic function hospitalized for heart failure: a report from the OPTIMIZE-HF Registry. 
  • Clinical application of cardiovascular pharmacogenetics. 
  • Clinical assessment of beta blockade. 
  • Clinical characteristics and outcomes of hospitalized heart failure patients with systolic dysfunction and chronic obstructive pulmonary disease: findings from OPTIMIZE-HF. 
  • Clinical effectiveness of beta-blockers in heart failure: findings from the OPTIMIZE-HF (Organized Program to Initiate Lifesaving Treatment in Hospitalized Patients with Heart Failure) Registry. 
  • Clinical features and contemporary management of patients with low and preserved ejection fraction heart failure: baseline characteristics of patients in the Candesartan in Heart failure-Assessment of Reduction in Mortality and morbidity (CHARM) programme. 
  • Clinical outcomes in patients on beta-blocker therapy admitted with worsening chronic heart failure. 
  • Clinical outcomes with β-blockers for myocardial infarction: a meta-analysis of randomized trials. 
  • Clinical physiology of adrenergic receptor regulation. 
  • Clinical trials in Japan and the United States. 
  • Cocaine directly augments the alpha-adrenergic contractile response of the pregnant rabbit uterus. 
  • Cocaine selectively inhibits beta-adrenergic receptor binding in pregnant human myometrium. 
  • Combinations of beta-blockers and calcium channel blockers: a cause of malignant perioperative conduction disturbances? 
  • Combinatorial pharmacogenetic interactions of bucindolol and β1, α2C adrenergic receptor polymorphisms. 
  • Comparative Effectiveness of Dosing of Medical Therapy for Heart Failure: From the CHAMP-HF Registry. 
  • Comparative Effectiveness of β-Blocker Use Beyond 3 Years After Myocardial Infarction and Long-Term Outcomes Among Elderly Patients. 
  • Comparative effectiveness of beta-blockers in elderly patients with heart failure. 
  • Comparative effectiveness of pharmacotherapies for prevention of atrial fibrillation following coronary artery bypass surgery. 
  • Comparison of long-term outcomes between older Asian and white patients with non-ST-segment elevation myocardial infarction: findings from CRUSADE-CMS database. 
  • Comparison of medical and surgical therapy for uncomplicated descending aortic dissection. 
  • Comparison of medical therapy dosing in outpatients cared for in cardiology practices with heart failure and reduced ejection fraction with and without device therapy: report from IMPROVE HF. 
  • Comparison of specificity of agonist and antagonist radioligand binding to beta adrenergic receptors. 
  • Concomitant use of a positive inotropic agent to create a bridge to the successful initiation of beta-blocker therapy in patients with heart failure: a proposal for a trial. 
  • Congenital long QT syndrome: considerations for primary care physicians. 
  • Consequences of growth hormone deficiency on cardiac structure, function, and beta-adrenergic pathway: studies in mutant dwarf rats. 
  • Contemporary Treatment Patterns and Clinical Outcomes of Comorbid Diabetes Mellitus and HFrEF: The CHAMP-HF Registry. 
  • Contextualizing Risk Among Patients With Heart Failure. 
  • Cost-effectiveness of screening for asymptomatic left ventricular dysfunction in childhood cancer survivors. 
  • Coupling of beta2-adrenoceptor to Gi proteins and its physiological relevance in murine cardiac myocytes. 
  • Current and novel pharmacologic approaches in advanced heart failure. 
  • Current use of beta blockers in patients with reactive airway disease who are hospitalized with acute coronary syndromes. 
  • Decrease in myometrial beta-adrenergic receptors with prenatal cocaine use. 
  • Delayed right heart failure following lung transplantation. 
  • Demographics, clinical characteristics, and outcomes of patients hospitalized for decompensated heart failure: observations from the IMPACT-HF registry. 
  • Determination of hospitalization type by investigator case report form or adjudication committee in a large heart failure clinical trial (β-Blocker Evaluation of Survival Trial [BEST]). 
  • Differences between agonist and antagonist binding following beta-adrenergic receptor desensitization. 
  • Differences in NT-proBNP Response and Prognosis in Men and Women With Heart Failure With Reduced Ejection Fraction. 
  • Differences in the Antinociceptive Effects and Binding Properties of Propranolol and Bupranolol Enantiomers. 
  • Direct binding studies of adrenergic receptors: biochemical, physiologic, and clinical implications. 
  • Discharge heart rate and β-blocker dose in patients hospitalized with heart failure: Findings from the OPTIMIZE-HF registry. 
  • Diuretics and sudden cardiac death. 
  • Do evidence-based treatments provide incremental benefits to patients with congestive heart failure already receiving angiotensin-converting enzyme inhibitors? A secondary analysis of one-year outcomes from the Assessment of Treatment with Lisinopril and Survival (ATLAS) study. 
  • Dose Response of β-Blockers in Adrenergic Receptor Polymorphism Genotypes. 
  • Dose-sensitive excitation and inhibition of spontaneous amygdala activity by propranolol. 
  • Dosing of beta-blocker therapy before, during, and after hospitalization for heart failure (from Organized Program to Initiate Lifesaving Treatment in Hospitalized Patients with Heart Failure). 
  • Dual inhibition of beta-adrenergic and angiotensin II receptors by a single antagonist: a functional role for receptor-receptor interaction in vivo. 
  • Early exercise training in patients older than age 65 years compared with that in younger patients after acute myocardial infarction or coronary artery bypass grafting. 
  • Early propranolol treatment induces lung heme-oxygenase-1, attenuates metabolic dysfunction, and improves survival following experimental sepsis. 
  • Early treatment for non-ST-segment elevation acute coronary syndrome is associated with appropriate discharge care. 
  • Economic effects of beta-blocker therapy in patients with heart failure. 
  • Editorial: Selectivity in beta-adrenergic responses: clinical implications. 
  • Effect of angiotensin-converting enzyme inhibitors, beta blockers, statins, and aspirin on C-reactive protein levels in outpatients with heart failure. 
  • Effect of autonomic blockade on the hemodynamic findings in acute cardiac tamponade. 
  • Effect of beta-adrenergic blockade and sympathetic stimulation on canine bronchial mast cell response to immune degranulation in vivo. 
  • Effect of beta-blocking therapy on outcome in the Multicenter UnSustained Tachycardia Trial (MUSTT). 
  • Effect of blood pressure lowering and antihypertensive drug class on progression of hypertensive kidney disease: results from the AASK trial. 
  • Effect of bucindolol on heart failure outcomes and heart rate response in patients with reduced ejection fraction heart failure and atrial fibrillation. 
  • Effect of catechol-O-methyltransferase polymorphism on response to propranolol therapy in chronic musculoskeletal pain: a randomized, double-blind, placebo-controlled, crossover pilot study. 
  • Effect of ramipril vs amlodipine on renal outcomes in hypertensive nephrosclerosis: a randomized controlled trial. 
  • Effect on Mortality of Higher Versus Lower β-Blocker (Metoprolol Succinate or Carvedilol) Dose in Patients With Heart Failure. 
  • Effects of beta-blockade and exercise on cardiovascular and cognitive functioning. 
  • Effects of beta-blockers on implantable cardioverter defibrillator therapy and survival in the patients with ischemic cardiomyopathy (from the Multicenter Automatic Defibrillator Implantation Trial-II). 
  • Effects of cardiovascular medications on rate of functional decline in Alzheimer disease. 
  • Effects of extended-release metoprolol succinate in patients undergoing non-cardiac surgery (POISE trial): a randomised controlled trial. 
  • Effects of gender and ethnic group on blood pressure control in the elderly. 
  • Effects of neurochemicals upon a dinoflagellate photoresponse. 
  • Effects of propranolol treatment on left ventricular function and intracellular calcium regulation in rats with postinfarction heart failure. 
  • Efficacy and tolerability of adding an angiotensin receptor blocker in patients with heart failure already receiving an angiotensin-converting inhibitor plus aldosterone antagonist, with or without a beta blocker. Findings from the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM)-Added trial. 
  • Efficacy of Flecainide in the Treatment of Catecholaminergic Polymorphic Ventricular Tachycardia: A Randomized Clinical Trial. 
  • Efficacy of drug therapy in the secondary prevention of cardiovascular disease and stroke. 
  • Electromechanical associations. 
  • Empagliflozin in the treatment of heart failure with reduced ejection fraction in addition to background therapies and therapeutic combinations (EMPEROR-Reduced): a post-hoc analysis of a randomised, double-blind trial. 
  • Enhanced adenylate cyclase activity of turkey erythrocytes following treatment with beta-adrenergic receptor antagonists. 
  • Epithelioid hemangioma responsive to oral propranolol. 
  • Evidence supporting secondary prevention strategies. 
  • Evidence-Based Process Performance Measures and Clinical Outcomes in Patients With Incident Heart Failure With Reduced Ejection Fraction: A Danish Nationwide Cohort Study. 
  • Evidence-based therapies and mortality in patients hospitalized in December with acute myocardial infarction. 
  • Factors related to heart rupture in acute coronary syndromes in the Global Registry of Acute Coronary Events. 
  • Failure of adjuvant heparin to reduce myocardial ischemia in the early treatment of patients with unstable angina. 
  • First experience with direct factor Xa inhibition in patients with stable coronary disease: a pharmacokinetic and pharmacodynamic evaluation. 
  • Food and Drug Administration: Cardiovascular and Renal Drugs Advisory Committee, 98th meeting, January 6th-7th, 2003. 
  • From guidelines to clinical practice: the impact of hospital and geographical characteristics on temporal trends in the management of acute coronary syndromes. The Global Registry of Acute Coronary Events (GRACE). 
  • Functional status, heart rate, and rhythm abnormalities in 521 Fontan patients 6 to 18 years of age. 
  • G protein-coupled receptor kinase 5 gene polymorphisms are associated with postoperative atrial fibrillation after coronary artery bypass grafting in patients receiving β-blockers. 
  • G-protein-coupled receptor kinase 4 polymorphisms and blood pressure response to metoprolol among African Americans: sex-specificity and interactions. 
  • Gadolinium cardiovascular magnetic resonance predicts reversible myocardial dysfunction and remodeling in patients with heart failure undergoing beta-blocker therapy. 
  • Gene signatures of postoperative atrial fibrillation in atrial tissue after coronary artery bypass grafting surgery in patients receiving β-blockers. 
  • Glaucoma. 
  • Guideline-Directed Medical Therapy Clinics: A Call to Action for the Heart Failure Team. 
  • Guidelines for the diagnosis and treatment of non-ST-segment elevation acute coronary syndromes. 
  • Gαi is required for carvedilol-induced β1 adrenergic receptor β-arrestin biased signaling. 
  • Heart Failure Complicated by Atrial Fibrillation: Don't Bury the Beta-Blockers Just Yet. 
  • Heart Rate or Beta-Blocker Dose? Association With Outcomes in Ambulatory Heart Failure Patients With Systolic Dysfunction: Results From the HF-ACTION Trial. 
  • Heart failure medications prescribed at discharge for patients with left ventricular assist devices. 
  • Heart failure preserved ejection fraction (HFpEF): an integrated and strategic review. 
  • Heart failure survival score in patients with Chagas disease: correlation with functional variables. 
  • Heart rate: a prognostic factor and therapeutic target in chronic heart failure. The distinct roles of drugs with heart rate-lowering properties. 
  • Heart Failure and Atrial Fibrillation, Like Fire and Fury. 
  • Hemodynamic and metabolic responses to exercise after adrenoceptor blockade in humans. 
  • Hepatic cyclic AMP generation and ornithine decarboxylase induction by glucagon and beta adrenergic agonists. 
  • Heterogeneity of adenylate cyclase-coupled beta-adrenergic receptors. 
  • History of hypertension, heart disease, and diabetes and ovarian cancer patient survival: evidence from the ovarian cancer association consortium. 
  • Hospital Variation in Adherence Rates to Secondary Prevention Medications and the Implications on Quality. 
  • Hospital variability in the rate of finding obstructive coronary artery disease at elective, diagnostic coronary angiography. 
  • How many patients with heart failure are eligible for cardiac resynchronization? Insights from two prospective cohorts. 
  • Hypertension with acute coronary syndrome and heart failure. 
  • Hypertensive heart failure: patient characteristics, treatment, and outcomes. 
  • ICDs Are Still an Effective Therapy to Prevent Sudden Cardiac Death in Heart Failure. 
  • INTERMACS (Interagency Registry for Mechanically Assisted Circulatory Support) Profiling Identifies Ambulatory Patients at High Risk on Medical Therapy After Hospitalizations for Heart Failure. 
  • Identification of adenylate cyclase-coupled beta-adrenergic receptors in frog erythrocytes with (minus)-[3-H] alprenolol. 
  • Identification of adenylate cyclase-coupled beta-adrenergic receptors with radiolabeled beta-adrenergic antagonists. 
  • Impact of acute beta-blocker therapy for patients with non-ST-segment elevation myocardial infarction. 
  • Impact of congestive heart failure in patients with non-ST-segment elevation acute coronary syndromes. 
  • Impact of diabetes on epidemiology, treatment, and outcomes of patients with heart failure. 
  • Impact of intravenous beta-blockade before primary angioplasty on survival in patients undergoing mechanical reperfusion therapy for acute myocardial infarction. 
  • Impact of nonfatal myocardial infarction on outcomes in patients with advanced heart failure and the effect of bucindolol therapy. 
  • Impaired expression and functional activity of the beta 3- and beta 1-adrenergic receptors in adipose tissue of congenitally obese (C57BL/6J ob/ob) mice. 
  • Implantable cardioverter defibrillator in high-risk long QT syndrome patients. 
  • Implementation of a Regional Network for ST-Segment-Elevation Myocardial Infarction (STEMI) Care and 30-Day Mortality in a Low- to Middle-Income City in Brazil: Findings From Salvador's STEMI Registry (RESISST). 
  • Implications of prior myocardial infarction for patients presenting with an acute myocardial infarction. 
  • Improved outcomes in peripartum cardiomyopathy with contemporary. 
  • In Response. 
  • Incidence and outcomes associated with early heart failure pharmacotherapy in patients with ongoing cardiogenic shock. 
  • Influence of beta-blocker continuation or withdrawal on outcomes in patients hospitalized with heart failure: findings from the OPTIMIZE-HF program. 
  • Influence of documented history of coronary artery disease on outcomes in patients admitted for worsening heart failure with reduced ejection fraction in the EVEREST trial. 
  • Influence of global region on outcomes in heart failure β-blocker trials. 
  • Influence of insurance type on the use of procedures, medications and hospital outcome in patients with unstable angina: results from the GUARANTEE Registry. Global Unstable Angina Registry and Treatment Evaluation. 
  • Inhibition of microglial superoxide anion production by isoproterenol and dexamethasone. 
  • Initial therapy of hypertension. 
  • Initiation, Continuation, Switching, and Withdrawal of Heart Failure Medical Therapies During Hospitalization. 
  • Inotropic drugs and neurohormonal antagonists in the treatment of HF in the elderly. 
  • Insidious-onset, non-wheezing carteolol-induced asthma in an atopic patient without asthma history. 
  • Insufficient reduction in heart rate during hospitalization despite beta-blocker treatment in acute decompensated heart failure: insights from the ASCEND-HF trial. 
  • Intensity and focus of heart failure disease management after hospital discharge. 
  • Intermittent pressure overload triggers hypertrophy-independent cardiac dysfunction and vascular rarefaction. 
  • International variation in characteristics and clinical outcomes of patients with type 2 diabetes and heart failure: Insights from TECOS. 
  • Intravenous Beta-Blockers for Cardioprotection in STEMI: The Saga Continues. 
  • Iodine-123 MIBG imaging before treatment of heart failure with carvedilol to predict improvement of left ventricular function and exercise capacity. 
  • Is Compliance With Surgical Care Improvement Project Cardiac (SCIP-Card-2) Measures for Perioperative β-Blockers Associated With Reduced Incidence of Mortality and Cardiovascular-Related Critical Quality Indicators After Noncardiac Surgery? 
  • Is diabetes mellitus-linked amino acid signature associated with β-blocker-induced impaired fasting glucose? 
  • Is heart failure guideline adherence being underestimated? The impact of therapeutic contraindications. 
  • Is rhythm control superior to rate control in patients with atrial fibrillation and congestive heart failure? 
  • Is rhythm-control superior to rate-control in patients with atrial fibrillation and diastolic heart failure? 
  • Isolated beta-adrenergic binding sites: a potential assay vehicle for catecholamines. 
  • Isolated hormone receptors: physiologic and clinical implications. 
  • Lack of association between adrenergic receptor genotypes and survival in heart failure patients treated with carvedilol or metoprolol. 
  • Lambert-Eaton myasthenic syndrome: clinical diagnosis, immune-mediated mechanisms, and update on therapies. 
  • Left ventricular dysfunction: causes, natural history, and hopes for reversal. 
  • Ligand-induced overexpression of a constitutively active beta2-adrenergic receptor: pharmacological creation of a phenotype in transgenic mice. 
  • Long-term Safety and Ocular Hypotensive Efficacy Evaluation of Netarsudil Ophthalmic Solution: Rho Kinase Elevated IOP Treatment Trial (ROCKET-2). 
  • Long-term adherence with cardiovascular drug regimens. 
  • Lovastatin and coadministered antihypertensive/cardiovascular agents. 
  • Low thromboembolism and pump thrombosis with the HeartMate II left ventricular assist device: analysis of outpatient anti-coagulation. 
  • Machine Learning Methods Improve Prognostication, Identify Clinically Distinct Phenotypes, and Detect Heterogeneity in Response to Therapy in a Large Cohort of Heart Failure Patients. 
  • Magnitude of abdominal incision affects the duration of postoperative ileus in rats. 
  • Major bleeding in patients with peripheral artery disease: Insights from the EUCLID trial. 
  • Management of Coronary Disease in Patients with Advanced Kidney Disease. 
  • Management of Heart Failure With Reduced Ejection Fraction. 
  • Management of Ventricular Arrhythmias and Sudden Cardiac Death Risk Associated With Cardiac Channelopathies. 
  • Management of glaucoma in pregnancy and lactation. 
  • Management of non-Q-wave myocardial infarction. 
  • Mavacamten Treatment for Obstructive Hypertrophic Cardiomyopathy: A Clinical Trial. 
  • Mavacamten for treatment of symptomatic obstructive hypertrophic cardiomyopathy (EXPLORER-HCM): a randomised, double-blind, placebo-controlled, phase 3 trial. 
  • Mechanism of action of intracisternal apolipoprotein A-IV in inhibiting gastric acid secretion in rats. 
  • Mechanisms of reflex bladder activation by pudendal afferents. 
  • Medical Management of Heart Failure With Reduced Ejection Fraction in Patients With Advanced Renal Disease. 
  • Medical Therapy During Hospitalization for Heart Failure With Reduced Ejection Fraction: The VICTORIA Registry. 
  • Medical Therapy for Heart Failure With Reduced Ejection Fraction: The CHAMP-HF Registry. 
  • Medical advances in the treatment of congestive heart failure. 
  • Medical records and quality of care in acute coronary syndromes: results from CRUSADE. 
  • Medical treatment of pregnancy hypertension. 
  • Medication Trajectory and Treatment Patterns in Medicare Patients With Heart Failure and Reduced Ejection Fraction. 
  • Medication dosing in outpatients with heart failure after implementation of a practice-based performance improvement intervention: findings from IMPROVE HF. 
  • Medication performance measures and mortality following acute coronary syndromes. 
  • Members of the G protein-coupled receptor kinase family that phosphorylate the beta2-adrenergic receptor facilitate sequestration. 
  • Meta-analysis: beta-blocker dose, heart rate reduction, and death in patients with heart failure. 
  • Metoprolol and coronary artery bypass grafting surgery: does intraoperative metoprolol attenuate acute beta-adrenergic receptor desensitization during cardiac surgery? 
  • Misperceptions about beta-blockers and diuretics: a national survey of primary care physicians. 
  • Modeling of sequestration and down regulation in cells containing beta2-adrenergic receptors. 
  • Modulation of experimental arthritis by vagal sensory and central brain stimulation. 
  • Mortality benefit of beta blockade in patients with acute coronary syndromes undergoing coronary intervention: pooled results from the Epic, Epilog, Epistent, Capture and Rapport Trials. 
  • Multifaceted intervention to promote beta-blocker use in heart failure. 
  • Multinational economic evaluation of valsartan in patients with chronic heart failure: results from the Valsartan Heart Failure Trial (Val-HeFT). 
  • National evaluation of adherence to beta-blocker therapy for 1 year after acute myocardial infarction in patients with commercial health insurance. 
  • Nebivolol in older adults with heart failure: reduced rates for seniors? 
  • Negative antagonists promote an inactive conformation of the beta 2-adrenergic receptor. 
  • Neuroprotection is associated with beta-adrenergic receptor antagonists during cardiac surgery: evidence from 2,575 patients. 
  • New York Heart Association functional class predicts exercise parameters in the current era. 
  • New developments in cardiovascular adrenergic receptor pharmacology: molecular mechanisms and clinical relevance. 
  • Norepinephrine: dissociation of -receptor binding from adenylate cyclase activation in solubilized myocardium. 
  • Novel insights into beta-blocker therapy for long QT syndromes. 
  • Ontogenetic transition of cardiac myosin heavy chain isoforms in rat ventricle: effects of fetal exposure to beta-adrenergic agonists or antagonists. 
  • Organized Program to Initiate Lifesaving Treatment in Hospitalized Patients with Heart Failure (OPTIMIZE-HF): rationale and design. 
  • Outcome in elderly patients undergoing primary coronary intervention for acute myocardial infarction: results from the Controlled Abciximab and Device Investigation to Lower Late Angioplasty Complications (CADILLAC) trial. 
  • Outcome in medically treated coronary artery disease. Ischemic events: nonfatal infarction and death. 
  • Outcomes associated with the use of secondary prevention medications after coronary artery bypass graft surgery. 
  • Outpatient management of heart failure in the United States, 2006-2008. 
  • Outpatient use of anticoagulants, rate-controlling drugs, and antiarrhythmic drugs for atrial fibrillation. 
  • Patient Perceptions and Familiarity With Medical Therapy for Heart Failure. 
  • Patterns and predictors of evidence-based medication continuation among hospitalized heart failure patients (from Get With the Guidelines-Heart Failure). 
  • Perioperative beta blockade in noncardiac surgery: a systematic review for the 2014 ACC/AHA guideline on perioperative cardiovascular evaluation and management of patients undergoing noncardiac surgery: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. 
  • Persistence with secondary prevention medications after acute myocardial infarction: Insights from the TRANSLATE-ACS study. 
  • Persistent Catechol-O-methyltransferase-dependent Pain Is Initiated by Peripheral β-Adrenergic Receptors. 
  • Perspectives on the genetic basis of opioid-induced hyperalgesia. 
  • Pharmacogenomics of Bucindolol in Atrial Fibrillation and Heart Failure. 
  • Pharmacogenomics of β-blockers and statins: possible implications for perioperative cardiac complications. 
  • Pharmacologic therapy for patients with chronic heart failure and reduced systolic function: review of trials and practical considerations. 
  • Pharmacological and emerging therapies in the treatment of chronic angina. 
  • Pharmacological management of atrial fibrillation in patients with heart failure with reduced ejection fraction: review of current knowledge and future directions. 
  • Pharmacological treatment of elderly patients with acute coronary syndromes without persistent ST segment elevation. 
  • Pharmacotherapy in Medicare beneficiaries with atrial fibrillation. 
  • Pharmacotherapy of social anxiety disorder. 
  • Pineal beta adrenergic receptor: correlation of binding of 3H-l-alprenolol with stimulation of adenylate cyclase. 
  • Polygenic Score for β-Blocker Survival Benefit in European Ancestry Patients With Reduced Ejection Fraction Heart Failure. 
  • Post-Myocardial Infarction Heart Failure. 
  • Potential impact of evidence-based medicine in acute coronary syndromes: insights from GUSTO-IIb. Global Use of Strategies to Open Occluded Arteries in Acute Coronary Syndromes trial. 
  • Poverty, process of care, and outcome in acute coronary syndromes. 
  • Predialysis systolic BP variability and outcomes in hemodialysis patients. 
  • Predicting maximal HR in heart failure patients on β-blockade therapy. 
  • Predictors of mortality after discharge in patients hospitalized with heart failure: an analysis from the Organized Program to Initiate Lifesaving Treatment in Hospitalized Patients with Heart Failure (OPTIMIZE-HF). 
  • Predictors of survival after cardiac arrest in outpatient hemodialysis clinics. 
  • Predictors, Trends, and Outcomes (Among Older Patients ≥65 Years of Age) Associated With Beta-Blocker Use in Patients With Stable Angina Undergoing Elective Percutaneous Coronary Intervention: Insights From the NCDR Registry. 
  • PredischaRge initiation of Ivabradine in the ManagEment of Heart Failure: Results of the PRIME-HF Trial. 
  • Predischarge initiation of carvedilol in patients hospitalized for decompensated heart failure. 
  • Predischarge initiation of carvedilol in patients hospitalized for decompensated heart failure: results of the Initiation Management Predischarge: Process for Assessment of Carvedilol Therapy in Heart Failure (IMPACT-HF) trial. 
  • Prehospital electrocardiograms (ECGs) do not improve the process of emergency department care in hospitals with higher usage of ECGs in non-ST-segment elevation myocardial infarction patients. 
  • Preoperative CYP2D6 metabolism-dependent β-blocker use and mortality after coronary artery bypass grafting surgery. 
  • Preoperative β-blocker use in coronary artery bypass grafting surgery: national database analysis. 
  • Prevention of atrial fibrillation by bucindolol is dependent on the beta₁389 Arg/Gly adrenergic receptor polymorphism. 
  • Prevention of sudden death in patients with coronary artery disease. 
  • Primary prevention implantable cardioverter-defibrillators and survival in older women. 
  • Prognosis and mechanism of death in treated heart failure: data from the placebo arm of Val-HeFT. 
  • Prognostic implications of ventricular arrhythmias during 24 hour ambulatory monitoring in patients undergoing cardiac catheterization for coronary artery disease. 
  • Prognostic significance of nonsustained ventricular tachycardia identified postoperatively after coronary artery bypass surgery in patients with left ventricular dysfunction. 
  • Projected Clinical Benefits of Implementation of SGLT-2 Inhibitors Among Medicare Beneficiaries Hospitalized for Heart Failure. 
  • Prophylactic defibrillator implantation in patients with nonischemic dilated cardiomyopathy. 
  • Prophylactic implantation of a defibrillator in patients with myocardial infarction and reduced ejection fraction. 
  • Prophylaxis against postoperative atrial fibrillation: current progress and future directions. 
  • Propranolol's potential to increase survival time in a disabled submarine. 
  • Prospective evaluation of beta-blocker use at the time of hospital discharge as a heart failure performance measure: results from OPTIMIZE-HF. 
  • Psychosocial and physical predictors of anginal pain relief with medical management. 
  • Quality of life after coronary angioplasty or continued medical treatment for angina: three-year follow-up in the RITA-2 trial. Randomized Intervention Treatment of Angina. 
  • Quality of medical care and excess mortality in older patients with mental disorders. 
  • Quantitative resolution of beta-adrenergic receptor subtypes by selective ligand binding: application of a computerized model fitting technique. 
  • Race, common genetic variation, and therapeutic response disparities in heart failure. 
  • Randomised trials of secondary prevention programmes in coronary heart disease: systematic review. 
  • Rate Control versus Rhythm Control for Atrial Fibrillation after Cardiac Surgery. 
  • Rationale and design of a randomized clinical trial of beta-blocker therapy (atenolol) versus angiotensin II receptor blocker therapy (losartan) in individuals with Marfan syndrome. 
  • Rationale and design of the Children's Oncology Group (COG) study ALTE1621: a randomized, placebo-controlled trial to determine if low-dose carvedilol can prevent anthracycline-related left ventricular remodeling in childhood cancer survivors at high risk for developing heart failure. 
  • Rationale and design of the GUIDE-IT study: Guiding Evidence Based Therapy Using Biomarker Intensified Treatment in Heart Failure. 
  • Rationale and design of the Initiation Management Predischarge: Process for Assessment of Carvedilol Therapy for Heart Failure (IMPACT-HF) study. 
  • Recent trends in the care of patients with non-ST-segment elevation acute coronary syndromes: insights from the CRUSADE initiative. 
  • Receptor crosstalk: effects of prolonged carbachol exposure on beta 1-adrenoceptors and adenylyl cyclase activity in neonatal rat ventricular myocytes. 
  • Receptor-specific desensitization with purified proteins. Kinase dependence and receptor specificity of beta-arrestin and arrestin in the beta 2-adrenergic receptor and rhodopsin systems. 
  • Red blood cell distribution width and 1-year mortality in acute heart failure. 
  • Regulation of beta adrenergic receptors in isolated frog erythrocyte plasma membranes. 
  • Regulation of lipoprotein metabolism by adrenergic mechanisms. 
  • Relation of Elevated Heart Rate in Patients With Heart Failure With Reduced Ejection Fraction to One-Year Outcomes and Costs. 
  • Relation of mortality to failure to prescribe beta blockers acutely in patients with sustained ventricular tachycardia and ventricular fibrillation following acute myocardial infarction (from the VALsartan In Acute myocardial iNfarcTion trial [VALIANT] Registry). 
  • Relation of patient age and mortality to reported contraindications to early beta-blocker use for non-ST-elevation acute coronary syndrome. 
  • Relationship between admission serum sodium concentration and clinical outcomes in patients hospitalized for heart failure: an analysis from the OPTIMIZE-HF registry. 
  • Relationship of beta-blocker dose with outcomes in ambulatory heart failure patients with systolic dysfunction: results from the HF-ACTION (Heart Failure: A Controlled Trial Investigating Outcomes of Exercise Training) trial. 
  • Relationships between emerging measures of heart failure processes of care and clinical outcomes. 
  • Renal insufficiency and heart failure: prognostic and therapeutic implications from a prospective cohort study. 
  • Reperfusion for acute myocardial infarction: is the future in plastics? 
  • Reply: Effect of Pre-Procedural β-Blocker in Patients Undergoing Percutaneous Coronary Intervention. 
  • Report from the 94th Cardiovascular and Renal Drugs Advisory Committee Meeting, October 11, 2001. 
  • Response to cardiac sympathetic activation in transgenic mice overexpressing beta 2-adrenergic receptor. 
  • Results of a pilot multicenter genotype-based randomized placebo-controlled trial of propranolol to reduce pain after major thermal burn injury. 
  • Rhythm control versus rate control for atrial fibrillation and heart failure. 
  • Rhythm versus rate control in the contemporary management of atrial fibrillation in-hospital. 
  • Risk stratification in the setting of non-ST elevation acute coronary syndromes 1999-2007. 
  • Role of beta-adrenergic receptor signaling and desensitization in heart failure: new concepts and prospects for treatment. 
  • Role of diuretics, β blockers, and statins in increasing the risk of diabetes in patients with impaired glucose tolerance: reanalysis of data from the NAVIGATOR study. 
  • Safety of nifedipine in angina pectoris: a meta-analysis. 
  • Safety of nifedipine in patients with hypertension: a meta-analysis. 
  • Secondary mitral and tricuspid regurgitation accompanying left ventricular systolic dysfunction: is it important, and how is it treated? 
  • Secondary prevention after coronary artery bypass graft surgery: findings of a national randomized controlled trial and sustained society-led incorporation into practice. 
  • Selective alteration in high affinity agonist binding: a mechanism of beta-adrenergic receptor desensitization. 
  • Serotonin-induced hypersensitivity via inhibition of catechol O-methyltransferase activity. 
  • Seven-transmembrane-spanning receptors and heart function. 
  • Sex influences on ventricular repolarization duration in normal subjects and in type 1, 2 and 3 long QT syndrome patients: Different effect in acquired and congenital type 2 LQTS. 
  • Sex-Stratified Trends in Enrollment, Patient Characteristics, Treatment, and Outcomes Among Non-ST-Segment Elevation Acute Coronary Syndrome Patients: Insights From Clinical Trials Over 17 Years. 
  • Simultaneous or Rapid Sequence Initiation of Quadruple Medical Therapy for Heart Failure-Optimizing Therapy With the Need for Speed. 
  • Social phobia: biological aspects and pharmacotherapy. 
  • Solubilization and characterization of the beta-adrenergic receptor binding sites of frog erythrocytes. 
  • Specific binding of -adrenergic catecholamines to a subcellular fraction from cardiac muscle. 
  • State-mandated continuing medical education and the use of proven therapies in patients with an acute myocardial infarction. 
  • Strategies to attenuate pathological remodeling in heart failure. 
  • Structure and function of beta-adrenergic receptors: regulation at the molecular level. 
  • Structure-activity relationships of adenylate cyclase-coupled beta adrenergic receptors: determination by direct binding studies. 
  • Surgical autonomic denervation results in altered colonic motility: an explanation for low anterior resection syndrome? 
  • Surrogate end points in heart failure trials. 
  • Synergistic effect of dexamethasone and isoproterenol on the expression of angiotensinogen in immortalized rat proximal tubular cells. 
  • Systemic timolol exposure following topical application to infantile hemangiomas. 
  • Target Doses of Heart Failure Medical Therapy and Blood Pressure: Insights From the CHAMP-HF Registry. 
  • Temporal trends for secondary prevention measures among patients hospitalized with coronary artery disease. 
  • Temporal trends in medical therapies for ST- and non-ST elevation myocardial infarction: (from the Atherosclerosis Risk in Communities [ARIC] Surveillance Study). 
  • The ABCs of managing systolic heart failure: Past, present, and future. 
  • The Association Between Beta-blocker and Renin-Angiotensin System Inhibitor Use After Heart Failure With Reduced Ejection Fraction Hospitalization and Outcomes in Older Patients. 
  • The Initiation Management Predischarge Process for Assessment of Carvedilol Therapy for Heart Failure (IMPACT-HF) Study: design and implications. 
  • The Use of Oral Beta-Blockers and Clinical Outcomes in Patients with Non-ST-Segment Elevation Acute Coronary Syndromes: a Long-Term Follow-Up Study. 
  • The association of admission heart rate and in-hospital cardiovascular events in patients with non-ST-segment elevation acute coronary syndromes: results from 135 164 patients in the CRUSADE quality improvement initiative. 
  • The benefit of implementing a heart failure disease management program. 
  • The beta-adrenergic receptor in heart failure. 
  • The beta-adrenergic receptor. 
  • The changing pattern of bacterial sepsis since the introduction of antibiotic therapy. 
  • The comparative effects of drive and test stimulus intensity on myocardial excitability and vulnerability. 
  • The effect of Rho-associated kinase inhibition on the ocular penetration of timolol maleate. 
  • The effect of beta-adrenergic blockers on the prognostic value of peak exercise oxygen uptake in patients with heart failure. 
  • The effect of medical therapy on IOP control in Ghana. 
  • The efficacy of azimilide in the treatment of atrial fibrillation in the presence of left ventricular systolic dysfunction: results from the Azimilide Postinfarct Survival Evaluation (ALIVE) trial. 
  • The global health and economic burden of hospitalizations for heart failure: lessons learned from hospitalized heart failure registries. 
  • The human placenta--a rich source of beta-adrenergic receptors: characterization of the receptors in particulate and solubilized preparations. 
  • The impact of aging on adrenergic receptor function: clinical and biochemical aspects. 
  • The impact of chronic obstructive pulmonary disease in patients hospitalized for worsening heart failure with reduced ejection fraction: an analysis of the EVEREST Trial. 
  • The impact of echocardiographic results on treatment decisions for patients suspected of mitral valve prolapse. 
  • The nature of treatment selection in coronary artery disease. Experience with medical and surgical treatment of a chronic disease. 
  • The relationship between magnitude of proteinuria reduction and risk of end-stage renal disease: results of the African American study of kidney disease and hypertension. 
  • The relaxant action of ritodrine, a sympathomimetic amine, on the uterus during term labor. 
  • The truth and consequences of the COURAGE trial. 
  • The use of beta-blockers in a tertiary care heart failure clinic: dosing, tolerance, and outcomes. 
  • The β-arrestin-biased β-adrenergic receptor blocker carvedilol enhances skeletal muscle contractility. 
  • Therapies to prevent heart failure post-myocardial infarction. 
  • Thyroid hormone regulation of beta-adrenergic receptor number. 
  • Timing of cardiac transplantation in patients with heart failure receiving beta-adrenergic blockers. 
  • Titration of medical therapy and clinical outcomes among patients with heart failure with reduced ejection fraction: Findings from the HF-ACTION trial. 
  • Titration of medications and outcomes in multi-ethnic heart failure cohorts (with reduced ejection fraction) from Singapore and New Zealand. 
  • Transiently overexpressed alpha2-adrenoceptors and their control of DNA synthesis in the developing brain. 
  • Treatment and outcomes in patients with myocardial infarction treated with acute β-blocker therapy: results from the American College of Cardiology's NCDR(®). 
  • Treatment and risk in heart failure: gaps in evidence or quality? 
  • Treatment disparities in the care of patients with and without diabetes presenting with non-ST-segment elevation acute coronary syndromes. 
  • Treatment gaps in the pharmacologic management of heart failure. 
  • Treatment of patients with myocardial infarction who present with a paced rhythm. 
  • Trends in the Use of Guideline-Directed Therapies Among Dialysis Patients Hospitalized With Systolic Heart Failure: Findings From the American Heart Association Get With The Guidelines-Heart Failure Program. 
  • Trends in the use of evidence-based treatments for coronary artery disease among women and the elderly: findings from the get with the guidelines quality-improvement program. 
  • Type II cell response to chronic beta adrenergic agonist and antagonist infusions. 
  • Under-utilisation of beta-blockers after acute myocardial infarction. Pharmacoeconomic implications. 
  • Unique Positive Cooperativity Between the β-Arrestin-Biased β-Blocker Carvedilol and a Small Molecule Positive Allosteric Modulator of the β2-Adrenergic Receptor. 
  • Update on the Impact of Comorbidities on the Efficacy and Safety of Heart Failure Medications. 
  • Use of Antiarrhythmic Medications in Medicare Part D Patients With an Implantable Cardioverter-Defibrillator and Ventricular Tachycardia. 
  • Use of beta-blockers in patients with an implantable cardioverter defibrillator. 
  • Use of continuous quality improvement to increase use of process measures in patients undergoing coronary artery bypass graft surgery: a randomized controlled trial. 
  • Use of evidence-based medical therapy in patients undergoing percutaneous coronary revascularization in the United States, Europe, and Canada. Coronary Angioplasty Versus Excisional Atherectomy Trial (CAVEAT-I) and Canadian Coronary Atherectomy Trial (CCAT) investigators. 
  • Use of guideline-recommended therapies for heart failure in the Medicare population. 
  • Use of resampling techniques to estimate the variance of parameters in pharmacological assays when experimental protocols preclude independent replication: an example using Schild regressions. 
  • Usefulness of beta blockers in high-risk patients after myocardial infarction in conjunction with captopril and/or valsartan (from the VALsartan In Acute Myocardial Infarction [VALIANT] trial). 
  • Utilization of secondary prevention therapies in patients with nonobstructive coronary artery disease identified during cardiac catheterization: insights from the National Cardiovascular Data Registry Cath-PCI Registry. 
  • Variation in use and dosing escalation of renin angiotensin system, mineralocorticoid receptor antagonist, angiotensin receptor neprilysin inhibitor and beta-blocker therapies in heart failure and reduced ejection fraction: Association of comorbidities. 
  • Vasodilator administration in the presence of beta-adrenergic blockade. 
  • When the heart runs out of heartbeats: treatment options for refractory end-stage heart failure. 
  • Which beta-blocker for heart failure? 
  • Which inhibitor of the renin-angiotensin system should be used in chronic heart failure and acute myocardial infarction? 
  • β blockers for heart failure: which works best? 
  • β-Adrenergic agonist and antagonist regulation of autophagy in HepG2 cells, primary mouse hepatocytes, and mouse liver. 
  • β-Adrenergic receptor antagonists ameliorate myocyte T-tubule remodeling following myocardial infarction. 
  • β-Arrestin-Biased Allosteric Modulator Potentiates Carvedilol-Stimulated β Adrenergic Receptor Cardioprotection. 
  • β-Blocker use and clinical outcomes in stable outpatients with and without coronary artery disease. 
• 

  Keywords of People

  • Alexander, John Hunter Peel, Professor of Medicine, Medicine, Cardiology
  • Curtis, Lesley H., Professor in Population Health Sciences, Medicine, General Internal Medicine
  • Middleton, John Paul, Professor of Medicine, Medicine, Nephrology
  • O'Connor, Christopher Michael, Adjunct Professor in the Department of Medicine, Medicine, Clinical Pharmacology